Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis

Urology

Volumn 55, Issue 1, 2000, Pages 36-40

  Tigrani, Vida S ^a   Reese, David M ^a   Small, Eric J ^a   Presti Jr , Joseph C ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLOXURIDINE; GAMMA INTERFERON; INTERLEUKIN 2; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033954720     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00395-7     Document Type: Article

References (25)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;8-31.
2. DeKernion J.B., Ramming K.P., Smith R.B. The natural history of metastatic renal cell carcinoma a computer analysis . J Urol. 120:1978;148-152.
3. Snow R.M., Schellhammer P.F. Spontaneous regression of metastatic renal cell carcinoma. Urology. 20:1982;177-181.
4. Johnson D.E., Kaesler K.E., Samuels M.L. Is nephrectomy justified in patients with metastatic renal cell carcinoma? J Urol. 114:1975;27-29.
5. Middleton A.W. Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol Clin North Am. 7:1980;711-717.
6. Krigel R.L., Padavic-Shaller K.A., Rudolph A.R., et al. Renal cell carcinoma treatment with recombinant interleukin-2 plus beta-interferon . J Clin Oncol. 8:1990;460-467.
7. Buzaid A.C., Robertone A., Kisala C., et al. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol. 5:1987;1083-1089.
8. Maldazys J.D., DeKernion J.B. Prognostic factors in metastatic renal carcinoma. J Urol. 136:1986;376-379.
9. Minasian L.M., Motzer R.J., Gluck L., et al. Interferon alfa-2a in advanced renal cell carcinoma treatment results and survival in 159 patients with long-term follow-up . J Clin Oncol. 11:1993;1368-1375.
10. Mani S., Todd M.B., Katz K., et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 154:1995;35-40.
11. Wolf J.S., Aronson F.R., Small E.J., et al. Nephrectomy for metastatic renal cell carcinoma a component of systemic treatment regimens . J Surg Oncol. 55:1994;7-13.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
13. Cox D. Regression models and life tables. J Roy Soc B. 34:1972;187-202.
14. Robertson C.N., Linehan W.M., Pass H.I., et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol. 144:1990;614-618.
15. Belldegrun A., Koo A.S., Bochner B., et al. Immunotherapy for advanced renal cell cancer the role of radical nephrectomy . Eur Urol. 18:(suppl 2):1990;42-45.
16. Naito S., Kimiya K., Sakamoto N., et al. Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma. Urology. 37:1991;95-99.
17. Walther M.M., Alexander R.B., Weiss G.H., et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology. 42:1993;250-258.
18. Rackley R., Novick A., Klein E., et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 152:1994;1399-1403.
19. Franklin J.R., Figlin R., Rauch J., et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma the UCLA experience . Semin Urol Oncol. 14:1996;230-236.
20. Levy D.A., Swanson D.A., Slaton J.W., et al. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 159:1998;1168-1173.
21. Krishnamurthi V., Novick A.C., Bukowski R.M. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology. 51:1998;933-937.
22. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma an analysis of 203 consecutively treated patients . Cancer J Sci Am. 3:1997;S92-S97.
23. Miyao N., Oda T., Shigyou M., et al. Pre-operatively determined prognostic factors in metastatic renal cell carcinoma. Eur Urol. 31:1997;292-296.
24. Bennett R.T., Lerner S.E., Taub H.C., et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol. 154:1995;32-34.
25. Spencer W.F., Linehan W.M., Walther M.M., et al. Immunotherapy with interleukin-2 and α-interferon in patients with metastatic renal cell carcinoma with in situ primary cancers a pilot study . J Urol. 147:1992;24-30.